z-logo
Premium
Profiling of Kidney Injury Biomarkers in Patients Receiving Cisplatin: Time‐dependent Changes in the Absence of Clinical Nephrotoxicity
Author(s) -
George B,
Wen X,
Mercke N,
Gomez M,
O'Bryant C,
Bowles DW,
Hu Y,
Hogan SL,
Joy MS,
Aleksunes LM
Publication year - 2017
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.606
Subject(s) - cisplatin , nephrotoxicity , medicine , urinary system , acute kidney injury , urology , creatinine , urine , kidney , renal function , lipocalin , subclinical infection , nephrology , chemotherapy
The success of cisplatin‐containing regimens to treat solid tumors is limited, in part, by nephrotoxicity. In rodents, several urinary proteins have emerged that are sensitive indicators of cisplatin‐induced kidney injury. We sought to characterize time‐dependent changes in the urinary concentrations of 12 proteins, including kidney injury molecule‐1 (KIM‐1), calbindin, beta 2‐microglobulin (β2M), and trefoil factor 3 (TFF3) after cisplatin therapy. Urine was collected at baseline, 3 days (range, 2–5 days), and 10 days (range, 9–11 days) from 57 patients with solid tumors receiving outpatient cisplatin therapy (≥25 mg/m 2 ). Serum creatinine was largely unchanged after cisplatin infusion. However, compared with baseline values, several novel biomarkers were significantly increased in the urine, including β2M, which was threefold higher by day 3 ( P < 0.0001). Urinary KIM‐1 and TFF3 were elevated twofold by day 10 ( P = 0.002 and P = 0.002, respectively), whereas calbindin levels were increased eightfold ( P < 0.0001). We report novel time‐dependent changes in the urinary excretion of noninvasive markers of subclinical kidney injury after cisplatin treatment.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here